The historical rank and industry rank for vTv Therapeutics's Net Margin % or its related term are showing as below:
VTVT'
s Net Margin % Range Over the Past 10 Years
Min: -5547.77 Med: -710.79 Max: 6.11
Current: 6.11
VTVT's Net Margin % is ranked better than 76.87% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs VTVT: 6.11
vTv Therapeutics (NAS:VTVT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
vTv Therapeutics Net Margin % Related Terms
vTv Therapeutics Net Margin % Historical Data
* Premium members only.
The historical data trend for vTv Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, vTv Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
vTv Therapeutics Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, vTv Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where vTv Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
vTv Therapeutics (VTVT) has a Net Margin % of 65.51% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on vTv Therapeutics and its competitors. According to the industry distribution chart, vTv Therapeutics ranks #219 out of 947 companies in the Biotechnology industry, placing it in the top 23.1%.
Is vTv Therapeutics' Net Margin % too high?
vTv Therapeutics' current Net Margin % is 65.51%. Based on the distribution chart, vTv Therapeutics ranks #219 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, vTv Therapeutics has a GF Score™ of 35/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does vTv Therapeutics' Net Margin % compare to CRDF and GUTS?
According to the Biotechnology industry distribution chart, vTv Therapeutics ranks #219 out of 947 companies for Net Margin %. This places vTv Therapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on vTv Therapeutics and its competitors. vTv Therapeutics's current Net Margin % is 65.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is vTv Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, vTv Therapeutics (VTVT) is currently considered Significantly Undervalued. The stock's GF Value™ is $7,827.31, compared to a current price of $36.82 — trading 99.5% below its estimated fair value. The current Net Margin % is 65.51%. vTv Therapeutics' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For vTv Therapeutics (VTVT), the current Net Margin % is 65.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is vTv Therapeutics (VTVT) Overvalued in 2026?
Based on GuruFocus' analysis, vTv Therapeutics stock appears to be undervalued.
The current stock price of $36.82 is trading 99.5% below its estimated GF Value™ of $7,827.31.
GuruFocus considers vTv Therapeutics to be Significantly Undervalued.
Key valuation signals for VTVT:
Net Margin %: 65.51%
GF Value™: $7,827.31 vs. price of $36.82 (99.5% below fair value)
No single metric tells the full story. See the VTVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
35GF Score
Get the complete analysis for VTVT
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VTVT has been successfully added to your 
